- Gonadotropin hormone
- Recombinant Follicle Stimulation Hormone
Male Infertility Treatment Market size was valued at USD 4.3 billion in 2022 and is poised to grow at a significant CAGR of 4.93% from 2023-2029. male infertility refers to the inability of male to cause pregnancy in a fertile woman. A variety of the problems ranging from hormonal disturbances to physical, psychological problems can cause male infertility. Hormonal problems include hyperprolactinemia, hypothyroidism, panhypopituitarism and others. Physical problems include varicocele, torsion, damaged sperm ducts and others. Furthermore, Erectile dysfunction, premature ejaculation and ejaculatory incompetence may lead to male infertility. Although many treatments are available for male infertility, in many cases treatment will not work. In many of the cases, male infertility is caused by testicular damage that leads to the inability of sperm production. In addition, low sperm production and poor sperm quality are also major causes of male infertility. Drugs, hormonal therapy, and assisted reproductive technology make up the global male infertility treatment market (ART). Clomiphene citrate and tamoxifen are two drugs used to treat male infertility. Human chorionic gonadotropin hormone (hCG) and recombinant follicle stimulating hormone (rFSH) are two types of hormone therapy (rFSH). Patients are given gonadotropin treatment to increase their testosterone levels. If these medicines do not work after 6 to 12 months of treatment, assisted reproductive technologies may be a possibility. In vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), frozen embryo transfer (FET), and zygote intrafallopian transfer (ZIFT) are the several types of assisted reproductive technologies (ZIFT).
Fastest Growing Market
The market is mainly driven by the steady increase in infertility rates globally. In addition, change in lifestyles and growing ageing population are also influencing the growth of the male infertility drugs market over the forecast period. Furthermore, recent advancements in infertility treatment and growing awareness related to the available treatment options and drugs are expected to bolster the market growth during the forecast period. However, unavailability of effective therapies or drugs for the treatment and social inhibitions are expected to hamper the male infertility drugs market during the forecast period. The market is driven by the steady growth rate in infertility, rising burden of conditions such as obesity and smoking around the world who are more susceptible to become infertile. Companies are focusing on the development of new treatment methods to cope with the increase in demand for the male infertility treatment.
2022 is the base year and 2029 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Male Infertility Treatment Market size was valued at USD 4.3 billion in 2022 and is poised to grow at a significant CAGR of 4.93% from 2023-2029.
The Male Infertility Treatment Market is experiencing growth due to increasing awareness, advancements in assisted reproductive technologies, and a rising prevalence of male infertility issues.